| CLBAX | SEBLX | CLBAX / SEBLX | |
| Total Expense Ratio | 0.58 | 0.99 | 59% |
| Annual Report Gross Expense Ratio | 0.58 | 0.99 | 59% |
| Fund Existence | 25 years | 88 years | - |
| Gain YTD | 7.963 | 5.438 | 146% |
| Front Load | 4% | 5% | 70% |
| Min. Initial Investment | 250 | 2500 | 10% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 285B | 997M | 28,586% |
| Annual Yield % from dividends | 1.80 | 1.25 | 144% |
| Returns for 1 year | 5.93 | 3.32 | 179% |
| Returns for 3 years | 41.26 | 40.06 | 103% |
| Returns for 5 years | 32.92 | 29.01 | 113% |
| Returns for 10 years | 93.63 | 80.16 | 117% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RRBGX | 189.49 | 1.12 | +0.59% |
| T. Rowe Price Blue Chip Growth R | |||
| TSRPX | 23.36 | N/A | N/A |
| Nuveen Quant Small Cap Equity Premier | |||
| GABPX | 56.81 | -0.15 | -0.26% |
| Goldman Sachs Equity Income P | |||
| FDAGX | 90.63 | -0.61 | -0.67% |
| Fidelity Advisor Consumer Staples A | |||
| RYOIX | 93.54 | -1.10 | -1.16% |
| Rydex Biotechnology Inv | |||